Inhibitors of measles virus

Antiviral Chemistry and Chemotherapy

Volumn 15, Issue 3, 2004, Pages 111-119

  Barnard, Dale L ^a  

^a UTAH STATE UNIVERSITY   (United States)

Author keywords

Antiviral; Inhibitors; Measles virus; Vaccine

Indexed keywords

3 DEAZA 5' NORARISTEROMYCIN; 5 ETHYNYL 1 (3 GAMMA RIBOFURANOSYLIMIDAZOLE) 4 CARBOXIMIDE; 5' NORARISTEROMYCIN; ADENOSINE DERIVATIVE; ALPHA INTERFERON; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; BRASSINOSTEROID; CERULENIN; COUMARIN DERIVATIVE; CROFELEMER; DP 107; ENFUVIRTIDE; GUANOSINE DERIVATIVE; IMMUNOGLOBULIN; KETOCONAZOLE; MEASLES VACCINE; MEVINOLIN; MICONAZOLE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N (6 AMINOHEXYL) 5 CHLORO 1 NAPHTHALENESULFONAMIDE; NEPLANOCIN A; POLYAMINOPROPANE SULFATE; PURINE DERIVATIVE; RIBAVIRIN; SPARFOSIC ACID; SUBSTANCE P; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIVIRAL ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; MEASLES; MEASLES VACCINATION; MEASLES VIRUS; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUBACUTE SCLEROSING PANENCEPHALITIS; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 2942737293     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020401500301     Document Type: Review

References (86)

1. Barclay AJ, Foster A & Sommer A (1987) Vitamin A supplements and mortality related to measles: a randomised clinical trial. British Medical Journal (Clinical Research Edition) 294:294-296.
2. Barnard, DL, Huffman JH, Sidwell RW & Meyerson LR (1993a) Anti-herpesvirus activity and mode of action of SP-303, a novel plant flavenoid. Chemotherapy 39:212-217.
3. Barnard, DL, Huffman JH, Sidwell RW & Meyerson LR (1993b) Mode of action of SP-303 against respiratory syncytial virus (RSV). Chemotherapy 39:203-211.
4. Barnard DL, Stowell VD, Seley K, Hegde, VR, Das SR, Rajappan VP, Schneller SW, Smee DF & Sidwell RW (2001) Inhibition of measles virus replication by 5′-nor carbocyclic analogues. Antiviral Chemistry & Chemotherapy 12:241-250.
5. Barnard DL (2002) Viramidine. Current Opinion in Investigational Drugs 3:1585-1589.
6. Barnard DL, Xu Z-Q, Stowell VD, Yuan H, Smee DF, Samy R, Sidwell RW, Nielsen MK, Sun L, Cao H, Li A, Quint C, Deignan J, Crabb J & Flavin MT (2002) Coumarins and pyranocoumarins, potential novel pharmacophores for inhibition of measles virus replication. Antiviral Chemistry & Chemotherapy 13:39-59.
7. Bedows E & Hatfield GM (1982) An investigation of the antiviral activity of Podophyllum peltatum. Journal of Natural Products 45:725-729.
8. Bell AF, Whitton JL & Fujinami RS (1997) Antisense-mediated resistance to measles virus infection in HeLa cells. Journal of Infectious Diseases 176:258-261.
9. Bolt G & Pedersen IR (1998) The role of subtilisin-like proprotein convertases for cleavage of the measles virus fusion glycoprotein in different cell types. Virology 252:387-398.
10. Bourinbaiar AS, Tan X & Nagorny R (1993) Inhibitory effect of coumarins on HIV-1 replication and cell-mediated or cell-free viral transmission. Acta Virologica 37:241-250.
11. Carlowe J (2003) MMR down, measles up. Nursing Standard 17:18-20.
12. Carmena J, Tornero C, Salcedo M, Perpinan J & Pons E (1996) Pneumonia caused by measles in a pregnant woman with HIV antibodies. Response to treatment with immunoglobulins. Enfermedades Infecciosas y Microbiologia Clinica 14:456-457.
13. Carter MJ & Ter Meulen V (1983) Subacute sclerosing panencephalitis: are antigenic changes involved in measles virus persistence? Progress in Brain Research 59:163-171.
14. Chen H-M & Hosmane RS (2001) Acyclic nucleoside/nucleotide analogues with an imidazole ring skeleton. Nucleosides, Nucleotides & Nucleic Acids 20:1599-1614.
15. Clements CJ & Cutts FT (1995) The epidemiology of measles: thirty years of vaccination. Current Topics in Microbiology & Immunology 191:13-33.
16. Cline JC, Nelson JD, Gerzon K, Williams RH & Delong DC (1969) in vitro antiviral activity of mycophenolic acid and its reversal by guanine-type compounds. Applied Microbiology 18:14-20.
17. Cos P, Hermans N, De Bruyne T, Apers S, Sindambiwe D, Vanden Berghe D, Pieters L & Vlietinck AJ (2002) Further evaluation of Rwandan medicinal plant extracts for their antimicrobial and antiviral activities. Journal of Ethnopharmacology 79:155-163.
18. Cosby SL, McQuaid S, Taylor MJ, Bailey M, Rima BK, Martin SJ & Allen IV (1989) Examination of eight cases of multiple sclerosis and 56 neurological and non-neurological controls for genomic sequences of measles virus, canine distemper virus, simian virus 5 and rubella virus. Journal of General Virology 70:2027-2036.
19. Coutsoudis A, Kiepiela P, Coovadia HM & Broughton M (1992) Vitamin A supplementation enhances specific IgG antibody levels and total lymphocyte numbers while improving morbidity in measles. Pediatric Infectious Disease Journal 11:203-209.
20. De Clercq E, Cools M & Balzarini J (1989 Homocysteine potentiates the antiviral and cytostatic activity of those nucleoside analogues that are targeted at S-adenosylhomocysteine hydrolase. Biochemical Pharmacology 38:1771-1778.
21. De Clercq E & Cools M (1985) Antiviral potency of adenosine analogues: correlation with inhibition of S-adenosylhomocysteine hydrolase. Biochemical & Biophysical Research Communications 129:306-311.
22. De Clercq E (1985) Antiviral and antimetabolic activities of neplanocins. Antimicrobial Agents & Chemotherapy 28:84-89.
23. De Clercq E, Cools M, Balzarini J, Snoeck R, Andrei G, Hosoya M, Shigeta S, Ueda T, Minakawa N & Matsuda A (1991) Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide and related compounds. Antimicrobial Agents & Chemotherapy 35:679-684.
24. D'Souza RM & D'Souza R (2002) Vitamin A for the treatment of children with measles-a systematic review. Journal of Tropical Pediatrics 48:323-327.
25. Esolen LM, Park SW, Hardwick JM & Griffin DE (1995) Apoptosis as a cause of death in measles virus-infected cells. Journal of Virology 69:3955-3958.
26. Forni AL, Schluger NW & Roberts RB Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clinical Infectious Diseases 19:454-462.
27. Gay NJ (2000) Eliminating measles-no quick fix. Bulletin of the World Health Organization 78:949.
28. Griffin DE (2003) Measles virus. In Fields Virology, vol. 1, 3rd edition. Edited by DM Knipe & PM Howley. Philadelphia: Lippincott-Raven, pp 1401-1440.
29. Gururangan S, Stevens RF & Morris DJ (1990) Ribavirin response in measles pneumonia. Journal of Infection 20:219-221
30. Hayashi T, Hayashi K, Maeda M & Kojima I (1996) Calcium spirulan, an inhibitor of enveloped virus replication, from a blue-green alga Spirulina platenis. Journal of Natural Products 59:83-87.
31. Hinman A (1999) Eradication of vaccine-preventable diseases. Annual Review of Public Health 20:211-229.
32. Hoppen T, Jacobi G & Rister M (2003) Subacute sclerosing panencephalitis (SSPE). Kliniscche Padiatrie 215:268-269.
33. Huang SP, Shieh GJ, Lee L, Teng HJ, Kao ST & Lin JG (1997) Inhibition effect of Shengma-Gegen-Tang on measles virus in Vero cells and human peripheral blood mononuclear cells. American Journal of Chinese Medicine 25:89-96.
34. Hussey GD & Klein M (1993) Routine high-dose vitamin A therapy for children hospitalized with measles. Journal of Tropical Pediatrics 39:342-345.
35. Jack S (2004) Review: existing epidemiological evidence does not show an association between mumps, measles, and rubella vaccination and autism. Evidence-Based Nursing 7:25.
36. Jefferson T, Price D, Demicheli V & Bianco (2003) Unintended events following immunization with MMR: a systematic review. Vaccine 21:3954-3960.
37. Jin L, Knowles WA, Rota PA, Bellini WJ & Brown DW (1998) Genetic and antigenic characterisation of the haemagglutinin protein of measles virus strains recently circulating in the UK. Virus Research 55:107-113.
38. Katayama Y, Shibahara K, Kohama T, Homma M & Hotta H (1997) Molecular epidemiology and changing distribution of genotypes of measles virus field strains in Japan. Journal of Clinical Microbiology 35:2651-2653.
39. Kawashima H, Mori T, Kashiwagi Y, Takekuma K, Hoshika A & Wakefield A (2000) Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism. Digestive Diseases & Sciences 45:723-729.
40. Khor IW, Lin T, Langedijk JP, Johnson JE & Manchester M (2002) Novel strategy for inhibiting viral entry by use of a cellular receptor-plant virus chimera. Journal of Virology 76:4412-4419.
41. Koschel K, Brinckmann U & Hoyningen-Huene VV (1995) Measles virus antisense sequences specifically cure cells persistently infected with measles virus. Virology 207:168-178.
42. Kosugi Y, Saito Y, Mori S, Baba M, Watanabe J & Shigeta S (1994) Antiviral activities of mizorbine and other monophosphate dehydrogenase inhibitors against several ortho- and paramyxoviruses, Antiviral Chemistry & Chemotherapy 5:366-371.
43. 46 interaction triggers CD-46 downregulation. Journal of General Virology 76:2793-2800.
44. Kurokawa M, Ochiai H, Nagasaka K, Neki M, Xu H, Kadota S, Sutardjo S, Matsumoto T, Namba T & Shiraki K (1993) Antiviral traditional medicines against herpes simplex virus (HSV-1), poliovirus, and measles virus in vitro and their therapeutic efficacies for HSV-1 infection in mice. Antiviral Research 22:175-188.
45. Laine D, Trescol-Biemont MC, Longhi S, Libeau G, Marie JC, Vidalain PO, Azocar O, Diallo A, Canard B, Rabourdin-Combe C & Valentin H (2003) Measles virus (MV) nucleoprotein binds to a novel cell surface receptor distinct from FcgammaRII via its C-terminal domain: role in MV-induced immunosuppression. Journal of Virology 77:11332-11346.
46. Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G & Petteway SR Jr (1996) Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proceedings of the National Academy of Sciences, USA 93:2186-2191.
47. Lavy A, Broide E, Reif S, Keter D, Niv Y, Odes S, Eliakim R, Halak A, Ron Y, Patz J, Fich A, Villa Y, Arber N & Gilat T (2001) Measles is more prevalent in Crohn's disease patients. A multicentre Israeli study. Digestive & Liver Disease 33:472-476.
48. LeDuc JW, Damon I, Relman DA, Huggins J & Jahrling PB (2002) Smallpox research activities: US interagency collaboration, 2001. Emerging Infectious Diseases 8:743-745.
49. Lin CC, Philips L, Xu C & Yeh LT (2004) Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. Journal of Clinical Pharmacology 44:265-275.
50. Lin YM, Flavin MT, Schure R, Chen FC, Sidwell R, Barnard DL, Huffman JH & Kern ER (1999) Antiviral activities of biflavonoids. Planta Medica 65:120-125.
51. Lobl TJ, Renis HE, Epand RM, Maggiora LL & Wathen MW (1988) Peptides as potential virus inhibitors. Synthesis and bioassay of five respiratory syncytial virus peptide analogues with antimeasles activity. International Journal of Peptide & Protein Research 32:326-330.
52. Malvoisin E & Wild F (1990) Effect of drugs which inhibit cholesterol synthesis on syncytia formation in Vero cells infected with measles virus. Biochimica Biophysica Acta 1042:359-364.
53. Manchester M, Naniche D & Stehle T (2000) CD46 as a measles receptor: form follows function. Virology 274:5-10.
54. McWhorter JH (1996) Spicebush. A Cherokee remedy for the measles. North Carolina Medical Journal 57:306.
55. Miller FA, Dixon GJ, Arnett G, Dice JR, Rightsel WA, Schabel FM Jr & McLean IW Jr (1968) Antiviral activity of carbobenzoxy di- and tripeptides on measles virus. Applied Microbiology 16:1489-1496.
56. Naniche D, Yeh A, Eto D, Manchester M, Friedman RM & Oldstone MBA (2000) Evasion of host defenses by measles virus: wild-type measles virus infection interferes with induction of alpha/beta interferon production. Journal of Virology 74:7478-7484.
57. Nicolaides E, DeWald H, Lipnik M, Westland R & Posler J (1968) Potential antiviral agents. Carbobenzoxy di- and tripeptides active against measles and herpes viruses. Journal of Medicinal Chemistry 11:74-79
58. Niizuma S, Shuto S & Matsuda A (1997) New neplanocin analogues. 10. The conversion of adenosine to neplanocin A, a carbocyclic nucleoside antibiotic with potent antiviral activity. Tetrahedron 53:13621-13632.
59. Patil SD, Schneller SW, Hosoya M, Snoeck R, Andrei G, Balzarini J, & De Clercq E (1992) Synthesis and antiviral properties of (+/-)-5′- noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design. Journal of Medicinal Chemistry 35:3372-3377.
60. Petricevich VL & Mendonca RZ (2003) Inhibitory potential of Crotolus durissus terrificus venom on measles virus growth. Toxicon 42:143-153.
61. Robins MJ, Samano V, Zhang W, Balzarini J, De Clercq E, Borchardt RT, Lee Y & Yuan CS. Nucleic acid related compounds. 74. Synthesis and biological activity of 2′(and 3′)-deoxy-(2′ and 3′)- methylenenucleoside analogues that function as mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase and/or ribonucleotide reductase. Journal of Medicinal Chemistry 35:2283-2293.
62. Ross AC (1998) Vitamin A supplementation as therapy-are the benefits disease-specific? American Journal of Clinical Nutrition 68:8-9.
63. Rota PA, Liffick SL, Rota JS, Katz RS, Redd S, Papania M & Bellini WJ (2002) Molecular epidemiology of measles viruses in the United States, 1997-2001. Emerging Infectious Diseases 8:902-908.
64. Rota PA & Bellini WJ (2003) Update on the global distribution of genotypes of wild type measles viruses. Journal of Infectious Diseases 187:S270-276.
65. Santibanez S, Tischer A, Heider A, Siedler A & Hengel H (2002) Rapid replacement of endemic measles virus genotypes. Journal of General Virology 83:2699-2708.
66. Schneider-Schaulies J, Meulen V & Schneider-Schaulies S (2003) Measles infection of the central nervous system. Journal of Neurovirology 9:247-252.
67. Schroeder C (1986) Substance P, a neuropeptide, inhibits measles virus replication in cell culture. Acta Virologica 30:432-435.
68. Sekiguchi J, Stivers JT, Mildvan AS, Shuman S (1996) Mechanism of inhibition of vaccinia DNA topoisomerase by novobiocin and coumermycin. Journal of Biology & Chemistry 271:2313-2322.
69. Seo SK, Malak SF, Lim S, Eagan J & Sepkowitz KA (2002) Prevalence of measles antibody among young adult healthcare workers in a cancer hospital: 1980s versus 1998-1999. Infection Control & Hospital Epidemiology 23:276-278.
70. Siddiqi SM, Chen X, Rao J, Schneller SW, Ikeda S, Snoeck R, Andrei G, Balzarini J, De Clercq E (1995) 3-deaza- and 7-deaza-5′-noraristeromycin and their antiviral properties. Journal of Medicinal Chemistry 38:1035-1038.
71. Shaffer JA, Bellini WJ & Rota PA (2003) The C protein of measles virus inhibits the type I interferon response. Virology 315:389-397.
72. Shigeta S, Mori S, Baba M, Ito M, Honzumi K, Nakamura K, Oshitani H, Numazaki Y, Matsuda A & Obara T (1992) Antiviral activities of ribavirin, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide, and 6′-(R)-6′-C-methylneplanocin A against several ortho- and paramyxoviruses. Antimicrobial Agents & Chemotherapy 36:435-439.
73. Singh VK & Jensen RL (2003) Elevated levels of measles antibodies in children with autism. Pediatric Neurology 28:292-294.
74. Skulnick HI, Johnson PD, Aristoff PA, Morris JK, Lovasz KD, Howe WJ, Watenpaugh KD, Janakiraman MN, Anderson DJ, Reischer RJ, Schwartz TM, Banitt LS, Tomich PK, Lynn JC, Horng MM, Chong KT, Hinshaw RR, Dolak LA, Seest EP, Schwende FJ, Rush BD, Howard GM, Toth LN, Wilkinson KR, Romines KR et al. (1997) Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones. Journal of Medicinal Chemistry 40:1149-1164.
75. Soldatou A & Davies EG (2003) Respiratory virus infections in the immunocompromised host. Paediatric Respiratory Reviews 4:193-204.
76. Steingart KR, Thomas AR, Dykewicz CA & Redd SC (1999) Transmission of measles virus in healthcare settings during a communitywide outbreak. Infection Control & Hospital Epidemiology 20:115-119.
77. Stogner SW, King JW, Black-Payne C & Bocchini J (1993) Ribavirin and intravenous immune globulin therapy for measles pneumonia in HIV infection. Southern Medical Journal 86:1415-1418.
78. Takeuchi K, Kadota SI, Takeda M, Miyajima N & Nagata K (2003) Measles virus V protein blocks interferon (IFN)-alpha/beta but not IFN-gamma signaling by inhibiting STAT1 and STAT2 phosphorylation. FEBS Letters 545:177-182.
79. Ubillas R, Jolad SD, Bruening RC, Kernan MR, King SR, Sesin DF, Barrett M, Stoddart CA, Flaster T, Kuo J, Ayala F, Meza E, Castanel M, McMeekin D, Rozhon E, Tempesta MS, Barnard D, Smee D, Sidwell R, Soike K, Brazier A, Safrin S, Orlando R, Kenney PTM, Berova N & Nakinishi K (1994) SP-303, an antiviral oligomeric proanthocyanidin from the latex of Croton lechleri (Sangre de Drago). Phytomedicine 1:77-106.
80. Wachsman MB, Ramirez JA, Galagovsky LR & Coto CE (2002) Antiviral activity of brassinosteroids derivatives against measles virus in cell cultures. Antiviral Chemistry & Chemotherapy 13:61-66.
81. Wyde PR, Meyerson LR & Gilbert BE (1993) An in vitro evaluation of the antiviral activity of SP-303, an Euphorbiaceae shrub extract, against a panel of respiratory viruses. Drug Development Research 28:467-472.
82. Wyde PR, Moore DK, Pimentel DM & Blough HA (1995) Evaluation of the antiviral activity of N-(phosphonoacetyl)-L-aspartate against Paramyxoviruses in tissue culture and against respiratory syncytial virus in cotton rats. Antiviral Research 27:59-69.
83. Wyde PR (1999) Chemotherapy of respiratory viruses: prospects and challenges. Drug Resistance Updates 2:244-258.
84. Wyde PR, Moore-Poveda DK, De Clercq E, Neyts J, Matsuda A, Minakawa N, Guzman E & Gilbert BE (2000) Use of cotton rats to evaluate the efficacy of antivirals in treatment of measles virus infections. Antimicrobial Agents & Chemotherapy 44:1146-1152.
85. Zhang N, Chen H-M, Sood R, Kalicharran, K, Fattom AI, Naso RB, Barnard DL, Sidwell, RW & Hosmane RS (2002) In vitro inhibition of the measles virus by novel ring-expanded ('Fat') nucleoside analogues containing the imidazo[4,5-e][1,3] diazepine ring system. Bioorganic & Medicinal Chemistry Letters 12:3391-3394.
86. Zorzon M, Zivadinov R, Nasuelli D, Dolfini P, Bosco A, Bratina A, Tommasi MA, Locatelli L & Cazzato G (2003) Risk factors of multiple sclerosis: a case-control study. Neurological Sciences 24:242-247.